TABLE-2 SUMMARY OF MIRABEGRON COMPARATIVE STUDIES ON BPH INDUCED OABS
AUTHORS STUDY NOS ARMS OF THE STUDY CONCLUSIONS
Ichihara et al (7)
RC
76
Tamsulosin 0.2mg + Mirabegron 50mg vs Tamsulosin 0.2mg (8 weeks)
Combination therapy with tamsulosin& mirabegron was effective in BPH with residual OABS postinitiation of tamsulosin
Kakizaki et al (8)
RC
568
Tamsulosin 0.2mg + Mirabegron 50mg Vs Tamsulosin 0.2mg+placebo (12 weeks)
Mirabegron add-on therapy to tamsulosin for 12wk in men with LUTS & OABS demonstrated superior efficacy to placebo with good tolerance
Kaplan et al (9)
RC
676
Tamsulosin 0.4mg + Mirabegron 50mg Vs Tamsulosin 0.4mg + placebo (12 weeks)
Mirabegron add on therapy was statistically significant in reducing OABS in comparison to placebo
Shunye Su et al (10)
MA
1317
Mirabegron + tamsulosin vs Tamsulosin (8-12 weeks)
Mirabegron was effective and safe treatment for OABS induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects.
Matsuo et al (11)
PA
50
Analysis of Mirabegron (50mg) add on therapy to α1 adrenergic blocker. (12 weeks)
Mirabegron add on therapy was effective in persistent OABS after α1 blockers in men with BPH.
Wada et al (12)
PA
26
Analysis of Mirabegron (50mg) add on therapy to pre-existing tamsulosin. (8 weeks)
Mirabegron add on treatment with tamsulosin was efficacious/safe in improving OABS without impairing bladder contractility in men with OAB.
Present Study
RC
100
Tamsulosin 0.4mg + Mirabegron 50mg vs Tamsulosin 0.4mg+Placebo(8 weeks)
Mirabegron & tamsulosin combination therapy was significantly efficacious and safe versus Tamsulosin monotherapy for BPH induced OABS without an increase in PVR/AUR.
PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms